IFNα has been used for decades, even in low-risk patients, and can lead to molecular responses in a both JAK2 and CALR mutated MPN patients; moreover, these responses can be maintained for several years after discontinuation of IFNα [37,38,39,40]. This evidence concerns the gene JAK2 and myeloproliferative disorder.